IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-wei

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging false advertising and deceptive marketi

Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading a

CNBC's Jim Cramer delivers his daily Mad Dash.

Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival o

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approac

Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Li

Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing ​the U.S.

In the latest trading session, Eli Lilly (LLY) closed at $1, marking a -2.73% move from the previous

Lilly stock has soared in the double-digits over the past couple of months. A potential stock split

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yie

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's co

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth explo

Boston Common Asset Management LLC cut its stake in shares of Eli Lilly and Company (NYSE: LLY) by 1

Broderick Brian C increased its position in shares of Eli Lilly and Company (NYSE: LLY) by 12.8% in

Decker Wealth Management LLC acquired a new stake in Eli Lilly and Company (NYSE: LLY) during the fi

AlTi Global Inc. boosted its stake in shares of Eli Lilly and Company (NYSE: LLY) by 29.8% in the un

The three biggest US pharma names by market cap trade at very different setups right now: Johnson &

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on div

Dorsey Wright and Associates purchased a new stake in Eli Lilly and Company (NYSE: LLY) during the f

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics,

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Lulu's Fashion Lounge Holdings (NASDAQ:LVLU) retained Solomon Partners as its financial advisor and

Deal Dispatch features companies for sale or bought — also off the block — and what bankruptcies are

Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results,

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psyched

For investors seeking to pare exposure to the artificial intelligence (AI) trade amid boom-induced v

Health stocks had a strong week, with some big firms seeing drugs approved. Eli Lilly (LLY) reported

Eli Lilly's first venture into psychedelic medicine, a takeover of AtaiBeckley worth up to $3.8 bill

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a c

AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lill

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history

UnitedHealth's (UNH) strong earnings and raised outlook lifted healthcare ETFs despite a sharp d

GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea

Eli Lilly and Co (NYSE:LLY) on Thursday agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal t

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression ther

The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings

U.S. stock futures declined on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices fell,

A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Med

A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Med

On CNBC's “Halftime Report Final Trades,” Bill Baruch, founder and CIO of both Blue Line Capital, an

Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) i

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, co

Eli Lilly and Company (NYSE:LLY) and AtaiBeckley Inc. (NASDAQ:ATAI), a clinical-stage biopharmaceuti

Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. AtaiBeckley is developing

AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) i

Eli Lilly is in talks to buy a psychedelic drugmaker at a premium, according to a report.